Cargando…

Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.

From 1972 to 1976, 95 patients with clinical stages I-IIIA Hodgkin's disease were treated by chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) before and after extended field radiotherapy. The CVPP schedule gave: (1) a constant drug dosage for each patient inde...

Descripción completa

Detalles Bibliográficos
Autores principales: Lagarde, P., Bonichon, F., Eghbali, H., de Mascarel, I., Chauvergne, J., Hoerni, B.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247159/
https://www.ncbi.nlm.nih.gov/pubmed/2713252
_version_ 1782150921818472448
author Lagarde, P.
Bonichon, F.
Eghbali, H.
de Mascarel, I.
Chauvergne, J.
Hoerni, B.
author_facet Lagarde, P.
Bonichon, F.
Eghbali, H.
de Mascarel, I.
Chauvergne, J.
Hoerni, B.
author_sort Lagarde, P.
collection PubMed
description From 1972 to 1976, 95 patients with clinical stages I-IIIA Hodgkin's disease were treated by chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) before and after extended field radiotherapy. The CVPP schedule gave: (1) a constant drug dosage for each patient independent of body surface or weight; and (2) a total drug dosage dependent on haematological tolerance, since the treatment was given for 21 days or until the leukocyte count dropped to 2 x 10(9) l-1. The drug dosage per unit body surface (or 'dose density') significantly correlates with the drop in leukocyte count (P less than 0.001) and the tumour regression at the end of the induction course (P = 0.020). Disease-free survival is significantly related to dose density (P = 0.050) but not to dose intensity calculated on the duration of treatment (P = 0.240). However, after exclusion of three marginal recurrences due to border-line radiotherapy, the dose intensity significantly correlates with the disease-free survival (P = 0.031) and with the duration of complete remission (r = 0.870).
format Text
id pubmed-2247159
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22471592009-09-10 Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease. Lagarde, P. Bonichon, F. Eghbali, H. de Mascarel, I. Chauvergne, J. Hoerni, B. Br J Cancer Research Article From 1972 to 1976, 95 patients with clinical stages I-IIIA Hodgkin's disease were treated by chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) before and after extended field radiotherapy. The CVPP schedule gave: (1) a constant drug dosage for each patient independent of body surface or weight; and (2) a total drug dosage dependent on haematological tolerance, since the treatment was given for 21 days or until the leukocyte count dropped to 2 x 10(9) l-1. The drug dosage per unit body surface (or 'dose density') significantly correlates with the drop in leukocyte count (P less than 0.001) and the tumour regression at the end of the induction course (P = 0.020). Disease-free survival is significantly related to dose density (P = 0.050) but not to dose intensity calculated on the duration of treatment (P = 0.240). However, after exclusion of three marginal recurrences due to border-line radiotherapy, the dose intensity significantly correlates with the disease-free survival (P = 0.031) and with the duration of complete remission (r = 0.870). Nature Publishing Group 1989-04 /pmc/articles/PMC2247159/ /pubmed/2713252 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Lagarde, P.
Bonichon, F.
Eghbali, H.
de Mascarel, I.
Chauvergne, J.
Hoerni, B.
Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.
title Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.
title_full Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.
title_fullStr Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.
title_full_unstemmed Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.
title_short Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.
title_sort influence of dose intensity and density on therapeutic and toxic effects in hodgkin's disease.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247159/
https://www.ncbi.nlm.nih.gov/pubmed/2713252
work_keys_str_mv AT lagardep influenceofdoseintensityanddensityontherapeuticandtoxiceffectsinhodgkinsdisease
AT bonichonf influenceofdoseintensityanddensityontherapeuticandtoxiceffectsinhodgkinsdisease
AT eghbalih influenceofdoseintensityanddensityontherapeuticandtoxiceffectsinhodgkinsdisease
AT demascareli influenceofdoseintensityanddensityontherapeuticandtoxiceffectsinhodgkinsdisease
AT chauvergnej influenceofdoseintensityanddensityontherapeuticandtoxiceffectsinhodgkinsdisease
AT hoernib influenceofdoseintensityanddensityontherapeuticandtoxiceffectsinhodgkinsdisease